|Regeneron Pharmaceuticals Inc -- USA Stock|| |
USD 433.82 0.84 0.19%
Executive VP of RandD
Dr. Neil Stahl, Ph.D., is Executive Vice President Research and Development Sciences of the Company. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction
Age: 59 EVP Since 2014 Ph.D
914 847-7000 www.regeneron.com
Stahl received his Ph.D. in Biochemistry from Brandeis University.
Neil Stahl Latest Insider Activity
The company has return on total asset (ROA)
of 14.77 %
which means that it generated profit of $14.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 24.06 %
meaning that it created $24.06 on every $100 dollars invested by stockholders.
The company currently holds 701.17 M in liabilities with Debt to Equity (D/E) ratio of 12.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals Inc has Current Ratio of 3.68 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals Inc (REGN) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 4,786 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.